Type 2 diabetes, chronic kidney disease, and mortality in patients with established cardiovascular disease

被引：0
|
作者：
Saely, C. H. [1 ]
Vonbank, A. [1 ]
Lins, C. [2 ]
Zanolin, D. [2 ]
Leiherer, A. [2 ]
Schuler, A. [1 ]
Rein, P. [1 ]
Muendlein, A. [2 ]
Mader, A. [3 ]
Schwerzler, P. [3 ]
Drexel, H. [4 ]
机构：
[1] Acad Teaching Hosp Feldkirch, Feldkirch, Austria
[2] Vorarlberg Inst Vasc Invest & Treatment, Feldkirch, Austria
[3] Private Univ Principal Liechtenstein, Triesen, Liechtenstein
[4] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1119
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [41] Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
    Charytan, David M.
    Solomon, Scott D.
    Ivanovich, Peter
    Remuzzi, Giuseppe
    Cooper, Mark E.
    McGill, Janet B.
    Parving, Hans-Henrik
    Parfrey, Patrick
    Singh, Ajay K.
    Burdmann, Emmanuel A.
    Levey, Andrew S.
    Eckardt, Kai-Uwe
    McMurray, John J. V.
    Weinrauch, Larry A.
    Liu, Jiankang
    Claggett, Brian
    Lewis, Eldrin F.
    Pfeffer, Marc A.
    DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1199 - 1208
  • [42] In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor
    Agarwal, R.
    Pitt, B.
    Rossing, P.
    Anker, S. D.
    Filippatos, G.
    Ruilope, L. M.
    Kovesdy, C. P.
    Tuttle, K.
    Vaduganathan, M.
    Wanner, C.
    Bansilal, S.
    Gebel, M.
    Joseph, A.
    Lawatscheck, R.
    Bakris, G.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2420 - 2420
  • [43] Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
    Nichols, Gregory A.
    Ustyugova, Anastasia V.
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    DIABETES, 2019, 68
  • [44] Associations of New-Onset Atrial Fibrillation With Risks of Cardiovascular Disease, Chronic Kidney Disease, and Mortality Among Patients With Type 2 Diabetes
    Geng, Tingting
    Wang, Yi
    Lu, Qi
    Zhang, Yan-Bo
    Chen, Jun-Xiang
    Zhou, Yan-Feng
    Wan, Zhenzhen
    Guo, Kunquan
    Yang, Kun
    Liu, Liegang
    Liu, Gang
    Pan, An
    DIABETES CARE, 2022, 45 (10) : 2422 - 2429
  • [45] THE IMPACT OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS ON SOCIAL COST IN CHRONIC KIDNEY DISEASE PATIENTS IN ITALY
    Bellelli, S.
    Turchetti, G.
    VALUE IN HEALTH, 2014, 17 (07) : A468 - A468
  • [46] Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
    Lautsch, Dominik
    Wang, Tongtong
    Yang, Lingfeng
    Rajpathak, Swapnil N.
    DIABETES THERAPY, 2019, 10 (06) : 2131 - 2137
  • [47] Cardioprotective Effect of Luseogliflozin in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Ina, Yujiro
    Kishi, Takuya
    Sekiguchi, Naotaka
    Sakane, Naoki
    DIABETES, 2019, 68
  • [48] Comorbidity Prevalence among Patients with Established Cardiovascular Disease and Type 2 Diabetes
    Iglay, Kristy
    Hannachi, Hakima
    Engel, Samuel S.
    Li, Xueying
    O'Connell, David
    Moore, Lori M.
    Rajpathak, Swapnil
    DIABETES, 2017, 66 : A404 - A404
  • [49] Comorbidity prevalence among patients with established cardiovascular disease and type 2 diabetes
    Hannachi, H.
    Iglay, K.
    Engel, S. S.
    Li, X.
    O'Connell, D.
    Moore, L. M.
    Rajpathak, S.
    DIABETOLOGIA, 2017, 60 : S517 - S517
  • [50] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
12345